Adam Levy's most recent trade in Nexgel Inc was a trade of 4,000 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on Aug. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.47 per share. | 28 Aug 2025 | 4,000 | 358,284 | - | 2.5 | 9,896 | Common Stock |
| Acrivon Therapeutics Inc | Adam Levy | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 01 Aug 2025 | 1,164 | 12,151 | - | 1.3 | 1,467 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 14.70 per share. | 28 Jul 2025 | 51,500 | 141,359 | - | 14.7 | 757,168 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 14.04 per share. | 28 Jul 2025 | 12,946 | 193,666 | - | 14.0 | 181,803 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 28 Jul 2025 | 8,425 | 132,934 | - | 15.1 | 127,203 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 28 Jul 2025 | 807 | 192,859 | - | 14.0 | 11,302 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 14.45 per share. | 11 Jul 2025 | 10,758 | 206,612 | - | 14.5 | 155,454 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.39 per share. | 09 Jun 2025 | 2,000 | 362,284 | - | 2.4 | 4,780 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.33 per share. | 09 Jun 2025 | 2,000 | 364,284 | - | 2.3 | 4,659 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 04 Jun 2025 | 1,000 | 366,284 | - | 2.3 | 2,323 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.29 per share. | 04 Jun 2025 | 1,000 | 367,284 | - | 2.3 | 2,290 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.22 per share. | 30 May 2025 | 1,000 | 368,284 | - | 2.2 | 2,220 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.58 per share. | 16 May 2025 | 1,000 | 369,284 | - | 2.6 | 2,575 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 11 Apr 2025 | 10,757 | 215,340 | - | 12.1 | 129,684 | Common Stock |
| Acrivon Therapeutics Inc | Adam Levy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 35,209 | 35,209 | - | - | Stock Option (Right to Buy) | |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.01 per share. | 01 Apr 2025 | 4,000 | 370,284 | - | 3.0 | 12,038 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 03 Mar 2025 | 4,000 | 374,284 | - | 3.2 | 12,639 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 170,000 | 170,000 | - | - | Stock Option | |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.64 per share. | 03 Feb 2025 | 4,000 | 378,284 | - | 3.6 | 14,558 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 9.09 per share. | 13 Jan 2025 | 10,657 | 226,197 | - | 9.1 | 96,901 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 13 Jan 2025 | 100 | 226,097 | - | 9.6 | 963 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 150,000 | - | - | Stock Options (right to buy) | |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 26,116 | 386,284 | - | 0 | Common Stock (restricted stock units) | |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 02 Jan 2025 | 4,000 | 382,284 | - | 4.0 | 15,828 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 20 Nov 2024 | 3,636 | 333,196 | - | 2.8 | 9,999 | Common Stock |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,818 | 1,818 | - | - | Warrant to Purchase Common Stock | |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 13.57 per share. | 11 Oct 2024 | 10,757 | 236,854 | - | 13.6 | 146,004 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 13.14 per share. | 11 Jul 2024 | 10,757 | 247,611 | - | 13.1 | 141,394 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 11 Jun 2024 | 96,815 | 255,462 | - | 12.9 | 1,252,718 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 200,000 | 200,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 20,000 | 20,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO, Chief Bus. Off. and Secy. | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 14 Feb 2023 | 6,250 | 350,811 | - | 16 | 100,000 | Common Stock |
| Mineralys Therapeutics Inc | Adam S. Levy | CFO, Chief Bus. Off. and Secy. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 97,518 | 97,518 | - | - | Stock Option | |
| Nexgel Inc | Adam Levy | Director, CEO | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 25 Mar 2022 | 1,250 | 295,408 | - | 1.9 | 2,360 | Common Stock |